Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | GLS | O94925 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PLEC | Q15149 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | TNKS | O95271 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29930611 | 1.00 | KDM4E (0.59) | KDM4ETP53TSHRGAAMAPK1 | |
| SCHEMBL1316368 | 0.98 | KDM4E (0.57) | KDM4ETP53TSHRGAAMAPK1 | |
| SCHEMBL1316369 | 0.98 | KDM4E (0.57) | KDM4ETP53TSHRGAAMAPK1 | |
| SCHEMBL16474145 | 0.78 | ALOX5 (0.59) | KDM4EALDH1A1ALOX5MPI | |
| SCHEMBL194708 | 0.78 | KDM4E (0.44) | KDM4ETP53TSHRGAAMAPK1 | |
| SCHEMBL19577293 | 0.76 | KDM4E (0.61) | KDM4ETP53TSHRGAAMAPK1 | |
| SCHEMBL7070837 | 0.75 | KDM4E (0.42) | KDM4ETP53TSHRGAAMEN1 | |
| SCHEMBL1618278 | 0.74 | KDM4E (0.59) | KDM4ETP53TSHRGAAMAPK1 | |
| SCHEMBL31091767 | 0.74 | KDM4E (1.00) | KDM4ETP53TSHRGAAMAPK1 | |
| SCHEMBL1101962 | 0.74 | KDM4E (1.00) | KDM4ETP53TSHRGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112689758-B | Device and method for checking the effect of a drug on microorganisms | 上海宜晟生物科技有限公司 | 2025-03-28 | — | — | CN | claimed |
| EP-4509172-A2 | ORAL AMINODIHYDROPHTHALAZINEDIONE COMPOSITIONS AND THEIR USE THE TREATMENT OF NON-VIRAL HEPATITIS | IMMUNOPHARMA PLUS D.O.O. (SI) | 2025-02-19 | — | — | EP | claimed |
| EP-3870175-B1 | ORAL AMINODIHYDROPHTHALAZINEDIONE COMPOSITIONS AND THEIR USE THE TREATMENT OF NON-VIRAL HEPATITIS | IMMUNOPHARMA PLUS D O O (SI) | 2024-08-28 | — | — | EP | claimed |
| CN-117589752-A | System and method for simultaneously realizing in-situ detection of Fe (II) and Mn (II) in seawater | 同济大学 | 2024-02-23 | — | — | CN | claimed |
| US-20240033349-A1 | VACCINE AND METHOD OF PROTECTION AGAINST CORONAVIRUS INFECTION | ABIDOV MUSA TAZHUDINOVICH (RU) | 2024-02-01 | — | — | US | claimed |
| CN-113929748-B | Kit for detecting BACE1 enzyme activity and application thereof | 中国科学技术大学 | 2023-10-20 | — | — | CN | claimed |
| US-20210379063-A1 | ORAL AMINODIHYDROPHTHALAZINEDIONE COMPOSITIONS AND THEIR USE IN THE TREATMENT OF NON-VIRAL HEPATITIS | IMMUNOPHARMA PLUS D.O.O. (SI) | 2021-12-09 | — | — | US | claimed |
| US-20200140450-A1 | CHEMICAL METHOD OF PRODUCING SMTP GROUPS OR SMTP-7 AND INTERMEDIATES USED IN THE METHOD | SHOWA UNIVERSITY (JP) | 2020-05-07 | — | — | US | claimed |
| EP-2508611-B1 | Process for production of triprenyl phenol compounds | TMS CO LTD (JP) | 2019-05-08 | — | — | EP | claimed |
| EP-3397257-A1 | COMPOSITIONS AND NETHODS FOR TREATING BRAIN DYSFUNCTION | Bach Pharma, Inc. (US) | 2018-11-07 | — | — | EP | claimed |
| EP-2508611-A1 | Process for production of triprenyl phenol compounds | Tokyo University of Agriculture and Technology TLO Co., Ltd. (JP) | 2012-10-10 | — | — | EP | claimed |
| US-20120100579-A1 | TRIPRENYL PHENOL COMPOUND, PROCESS FOR PRODUCTION OF TRIPRENYL PHENOL COMPOUND, AND THROMBOLYSIS ENHANCER | TOKYO UNIVERSITY OF AGRICLATURE AND TECHNOLOGY TLO CO., LTD. (JP) | 2012-04-26 | — | — | US | claimed |
| US-20110275642-A1 | NEW METHOD FOR OBTAINING 5-AMINO 2,3-DIHYDROPHTHALAZINE-1,4-DIONE ALKALI METAL SALTS AND THEIR USE IN MEDICINE | Abidopharma PL SP. Z.O.O. (PL) | 2011-11-10 | — | — | US | claimed |
| US-8048642-B2 | Heme choline esters and uses thereof | GENERAL ELECTRIC COMPANY (US) | 2011-11-01 | — | — | US | claimed |
| US-20090216028-A1 | Triprenyl phenol compound, process for production of triprenyl phenol compound, and thrombolysis enhancer | TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY TLO CO., LTD. (JP) | 2009-08-27 | — | — | US | claimed |
| US-20090155829-A1 | HEME CHOLINE ESTERS AND USES THEREOF | GENERAL ELECTRIC COMPANY (US) | 2009-06-18 | — | — | US | claimed |
| EP-2000540-A9 | TRIPRENYL PHENOL COMPOUND, PROCESS FOR PRODUCTION OF TRIPRENYL PHENOL COMPOUND, AND THROMBOLYSIS ENHANCER | Tokyo University of Agriculture and Technology TLO Co., Ltd. (JP) | 2009-03-25 | — | — | EP | claimed |
| EP-2000540-A2 | TRIPRENYL PHENOL COMPOUND, PROCESS FOR PRODUCTION OF TRIPRENYL PHENOL COMPOUND, AND THROMBOLYSIS ENHANCER | Tokyo University of Agriculture and Technology TLO Co., Ltd. (JP) | 2008-12-10 | — | — | EP | claimed |
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | claimed |
| EP-0414730-B1 | Chemical Compounds and pharmaceutical compositions capable of releasing a drug | MILLS RANDELL L (US) | 1999-12-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | APEH, PAH, ALAD | KDM4E 3072/4885TP53 2677/4885TSHR 3654/4885 |
| US-20110275642-A1 | NEW METHOD FOR OBTAINING 5-AMINO 2,3-DIHYDROPHTHALAZINE-1,4-DIONE ALKALI METAL SALTS AND THEIR USE IN MEDICINE | ADH1C, SCN5A, ADH1A | KDM4E 2263/4885TP53 2286/4885TSHR 3071/4885 |
| US-20200140450-A1 | CHEMICAL METHOD OF PRODUCING SMTP GROUPS OR SMTP-7 AND INTERMEDIATES USED IN THE METHOD | TST, SMS, TMSB4X | KDM4E 2155/4885TP53 3584/4885TSHR 957/4885 |
| US-20090155829-A1 | HEME CHOLINE ESTERS AND USES THEREOF | BCHE, ACHE, CHKB | KDM4E 613/4885TP53 4303/4885TSHR 2878/4885 |
| US-20090216028-A1 | Triprenyl phenol compound, process for production of triprenyl phenol compound, and thrombolysis enhancer | PLAT, F2R, F12 | KDM4E 2025/4885TP53 4117/4885TSHR 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.